Drug Type Biological products |
Synonyms KB-195-Kaleido Biosciences |
Target- |
Action modulators |
Mechanism Microbiome modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperammonemia | Phase 2 | - | - | |
Urea Cycle Disorders, Inborn | Preclinical | United Kingdom | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | Switzerland | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | Spain | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | Turkey | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | Belgium | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | United States | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | Germany | 17 Sep 2019 |